Nevin Murray

8.4k total citations · 3 hit papers
121 papers, 6.2k citations indexed

About

Nevin Murray is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Nevin Murray has authored 121 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 30 papers in Molecular Biology. Recurrent topics in Nevin Murray's work include Lung Cancer Research Studies (53 papers), Lung Cancer Treatments and Mutations (38 papers) and Neuroendocrine Tumor Research Advances (25 papers). Nevin Murray is often cited by papers focused on Lung Cancer Research Studies (53 papers), Lung Cancer Treatments and Mutations (38 papers) and Neuroendocrine Tumor Research Advances (25 papers). Nevin Murray collaborates with scholars based in Canada, United States and United Kingdom. Nevin Murray's co-authors include Joseph L. Pater, William K. Evans, Andrew Arnold, Yvon Cormier, Ronald Feld, Scott Tyldesley, Benny Zee, E Rapp, Michael McKenzie and Howard Pai and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Nevin Murray

119 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

1988 544 citations Joseph L. Pater, Yvon Cormier et al. Journal of Clinical Oncology profile →
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1993 515 citations Nevin Murray, Joseph L. Pater et al. Journal of Clinical Oncology profile →
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

2016 505 citations Scott Tyldesley, Nevin Murray et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers

Countries citing papers authored by Nevin Murray

Since Specialization

Citations

This map shows the geographic impact of Nevin Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nevin Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nevin Murray more than expected).

Fields of papers citing papers by Nevin Murray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nevin Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nevin Murray. The network helps show where Nevin Murray may publish in the future.

Co-authorship network of co-authors of Nevin Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Nevin Murray. A scholar is included among the top collaborators of Nevin Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nevin Murray. Nevin Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population 2015 ·Clinical Oncology ·Krista Noonan, (unknown), Janessa Laskin, Yulong Zheng, B. Melosky, Sophie Sun, Nevin Murray, Cheryl Ho	4
2	Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib 2014 ·Canadian Urological Association Journal ·Suzanne Richter, Jo-An Seah, Gregory R. Pond, Hui Gan, Mary J. MacKenzie, Sébastien J. Hotte, Som D. Mukherjee, Nevin Murray, Christian Kollmannsberger, Daniel Y.C. Heng, Masoom A. Haider, (unknown), S. Percy Ivy, Malcolm J. Moore, Srikala S. Sridhar	2
3	A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium 2013 ·Investigational New Drugs ·Srikala S. Sridhar, Mary J. MacKenzie, Sébastien J. Hotte, Som D. Mukherjee, Ian F. Tannock, Nevin Murray, Christian Kollmannsberger, Masoom A. Haider, Eric X. Chen, (unknown), Lisa Wang, S. Percy Ivy, Malcolm J. Moore	20
4	Stage III Non–Small-Cell Lung Cancer: Population-Based Patterns of Treatment in British Columbia, Canada 2012 ·Journal of Thoracic Oncology ·Shalini Vinod, Elaine S. Wai, Cheryl Alexander, Scott Tyldesley, Nevin Murray	31
5	Stage I Non-small Cell Lung Cancer (NSCLC) in Patients Aged 75 Years and Older: Does Age Determine Survival After Radical Treatment? 2010 ·Journal of Thoracic Oncology ·David A. Palma, Scott Tyldesley, (unknown), Islam Mohamed, Sally Smith, Elaine S. Wai, Nevin Murray, Suresh Senan	32
6	A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer 2009 ·Annals of Oncology ·Jorg Michels, Susan Ellard, Lyly Le, Christian Kollmannsberger, Nevin Murray, Emma S. Tomlinson Guns, Robert Carr, K.N. Chi	18
7	A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer 2009 ·Cancer ·Daniel Y.C. Heng, Kim N., Nevin Murray, Tao Jin, Jorge A. García, Ronald M. Bukowski, Brian I. Rini, Christian Kollmannsberger	50
8	Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia 2008 ·Lung Cancer ·Christopher W. Lee, Nevin Murray, Helén Anderson, Sanjay C. Rao, (unknown)	44
9	WS-07: Designs for vaccine and immunotherapy trials 2007 ·Journal of Thoracic Oncology ·KyungMann Kim, Nevin Murray	1
10	The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group 2007 ·Annals of Oncology ·Scott A. Laurie, Keyue Ding, (unknown), Ronald Feld, Nevin Murray, F. Shepherd, Lesley Seymour	10
11	B1-01: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis 2007 ·Journal of Thoracic Oncology ·Charles Butts, Andrew W. Maksymiuk, Glenwood Goss, Denis Soulières, Ernie Marshall, Yvon Cormier, Peter Ellis, Allan Price, Ravinder Sawhney, Nevin Murray	36
12	P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice 2007 ·Journal of Thoracic Oncology ·Christopher W. Lee, Nevin Murray, Helén Anderson, (unknown)	5
13	Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation 2003 ·Seminars in Oncology ·Sara Erridge, Nevin Murray	27
14	Carboplatin and Vinblastine for the Treatment of Metastatic Transitional Cell Carcinoma of the Urothelial Tract 2002 ·American Journal of Clinical Oncology ·(unknown), Kennard Tan, Kim N., C. Bryce, Nevin Murray, Chris Coppin	1
15	Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. 1997 ·Journal of Clinical Oncology ·Malcolm J. Moore, Ian F. Tannock, D. Scott Ernst, S. Huan, Nevin Murray	222
16	Second Primary Cancers Related to Smoking and Treatment of Small-Cell Lung Cancer 1997 ·JNCI Journal of the National Cancer Institute ·Margaret A. Tucker, Nevin Murray, Edward G. Shaw, David S. Ettinger, M Mabry, Martin H. Huber, (unknown), F. Shepherd, Douglas H. Johnson, Scott Grant, Joseph Aisner, Bruce E. Johnson, (unknown)	167
17	Influence of age in the treatment of limited-stage small-cell lung cancer 1996 ·Pneumologie ·L.L. Siu, Frances A. Shepherd, Nevin Murray, R. Feld, Joseph L. Pater, Benny Zee	1
18	Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer 1994 ·International Journal of Radiation OncologyBiologyPhysics ·Peter Coy, D. Ian Hodson, Nevin Murray, (unknown), David G. Payne, Andrew Arnold, Edmund Kostashuk, Peter Dixon, William K. Evans, Benny Zee, Anna Sadura, Joseph Ayoub, (unknown), Rafal Wierzbicki, Ronald Feld, Jean A. Maroun, Kenneth A. Wilson	17
19	Brief Intensive Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: A Phase II Study of the Weekly CODE Regimen 1991 ·JNCI Journal of the National Cancer Institute ·Nevin Murray, David Osoba, Amil M. Shah, (unknown), (unknown), C. C. Little	13
20	A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma 1988 ·Investigational New Drugs ·Elizabeth A. Eisenhauer, William K. Evans, Nevin Murray, Walter Kocha, Rafal Wierzbicki, Kenneth S. Wilson	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact